Humoral Vaccine Responses and One-year Follow-up of Infants Potentially Exposed to Ocrelizumab During Pregnancy and Breastfeeding - Part 1
In part one of this series, Dr. Justin Abbatemarco and Dr. Ruth Dobson discuss current evidence on monoclonal antibodies in pregnancy and breastfeeding and prior understanding of CD20 therapies. Read…
Read the full articleYou might also wanna read
Q&A 172: the OVERLORD-MS study
Rituximab vs. Ocrelizumab; which is superior?
Rituximab Noninferior to Ocrelizumab in Relapsing MS
Rituximab is noninferior to ocrelizumab in suppressing disease activity in newly diagnosed multiple sclerosis, with a similar incidence of a
A Long-Term Follow-Up Trial for Participants Enrolled in CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) Trials
Conditions : Participants Treated With Senza5 Interventions : Biological: Senza5 CART5 Sponsors : Vittoria Biotherapeutics Not yet recruitin
Clinical perspectives on herbal galactagogues in lactation care: a nationwide cross-sectional survey of Indian gynaecologists
Background: Breastfeeding is a biologically complex process with critical implications for maternal and infant health. Despite strong global
Study of HIV-Exposed Pregnancies and Transplacental Antibody Delivery Following RSVpreF
Conditions : RSV Immunization; HIV Interventions : Drug: RSVpreF Sponsors : University of British Columbia; Women's Health Research Institut
Teva et Polpharma Biologics s’associent pour un biosimilaire contre la sclérose en plaques
Les laboratoires Teva et Polpharma Biologics ont signé un accord de licence mondial portant sur un candidat biosimilaire à l’Ocrevus (ocreli
Comments
Sign in to join the conversation.
No comments yet. Be the first.